Dana-Far­ber CEO Lau­rie Glim­ch­er re­signs from GSK board — is she the next NIH di­rec­tor nom­i­nee?

GSK an­nounced this morn­ing in a Lon­don Stock Ex­change fil­ing that Lau­rie Glim­ch­er, pres­i­dent and CEO of the Dana-Far­ber Can­cer In­sti­tute, has ad­vised the com­pa­ny of her in­ten­tion to re­tire from its board of di­rec­tors on Oct. 13.

The com­pa­ny did not dis­close why Glim­ch­er has de­cid­ed to move on now af­ter more than five years as a non-ex­ec­u­tive di­rec­tor, but Glim­ch­er’s ap­point­ment her­ald­ed a much big­ger in­ter­est in on­col­o­gy at GSK, and she’s mov­ing on now as GSK’s R&D chief Hal Bar­ron al­so hits the ex­it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER